TOP
0
0
【簡體曬書節】 單本79折,5本7折,優惠只到5/31,點擊此處看更多!
State of Washington v. US Food & Drug Administration [Annotated]
滿額折

State of Washington v. US Food & Drug Administration [Annotated]

商品資訊

定價
:NT$ 686 元
領券後再享88折起
無庫存,下單後進貨(到貨天數約30-45天)
可得紅利積點:20 點
相關商品
商品簡介

商品簡介

This opinion is annotated by Nimble Books AI and includes a Foreword by Cincinattus [AI]; a variety of pithy, opinionated abstracts including scientific style, tldr, tldr one word, Explain It to Me Like I'm Five Years Old, and Action Items; tools for viewpoint diversity such as Dissents, Red Team Critiques, and MAGA Perspectives; a recursive summary with synopsis; and a virtual context summary. Cover art by Nimble Books AI.


AI summary:


This document is a court order granting in part a preliminary injunction sought by plaintiffs against the U.S. Food and Drug Administration (FDA) regarding the regulation of mifepristone, a medication used for medication abortion. The court order was issued by United States District Judge Thomas O. Rice in the Eastern District of the United States on April 7, 2023. The plaintiffs argue that the FDA's current Risk Evaluation and Mitigation Strategy (REMS) for mifepristone, which includes restrictions on distribution and administration, is unnecessary and imposes undue burdens on patients and healthcare providers, particularly during the COVID-19 pandemic. The court finds that there are serious issues going to the merits of the plaintiffs' claims under the Administrative Procedure Act (APA) and that the alleged unrecoverable economic costs in this case are sufficient to demonstrate irreparable harm. The court grants the preliminary injunction in part, enjoining the FDA from enforcing the in-person dispensing requirement for mifepristone during the COVID-19 pandemic and maintaining the status quo of the current REMS program until a determination on the merits.

The court order also denied a third party's unopposed motion for leave to file an amicus curiae brief, noting that the proposed brief offered no additional legal or substantive information that was particularly helpful to the court's findings on the present motion. The court stated that the brief may be more useful during a trial on the merits. The court directed the District Court Executive to enter the order and furnish copies to counsel. No bond shall be required pursuant to Federal Rule of Civil Procedure 65(c).

Overall, this document represents a legal decision in a case involving access to medication abortions during the COVID-19 pandemic. The court order grants a preliminary injunction in part against the FDA's current REMS program for mifepristone and denies a third party's motion for leave to file an amicus curiae brief.


您曾經瀏覽過的商品

購物須知

外文書商品之書封,為出版社提供之樣本。實際出貨商品,以出版社所提供之現有版本為主。部份書籍,因出版社供應狀況特殊,匯率將依實際狀況做調整。

無庫存之商品,在您完成訂單程序之後,將以空運的方式為你下單調貨。為了縮短等待的時間,建議您將外文書與其他商品分開下單,以獲得最快的取貨速度,平均調貨時間為1~2個月。

為了保護您的權益,「三民網路書店」提供會員七日商品鑑賞期(收到商品為起始日)。

若要辦理退貨,請在商品鑑賞期內寄回,且商品必須是全新狀態與完整包裝(商品、附件、發票、隨貨贈品等)否則恕不接受退貨。

定價:100 686
無庫存,下單後進貨
(到貨天數約30-45天)

暢銷榜

客服中心

收藏

會員專區